Home LiteratureArticle Details
PMID: 26989092 Published · ppublish English Journal Article Review Research Support, Non-U.S. Gov't

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.

International immunology ·Vol. 28 ·No. 8 ·2016-00-00 ·Pages 383-91

Spranger S

Abstract

Checkpoint blockade therapy has been proven to be highly active across many cancer types but emerging evidence indicates that the therapeutic benefit is limited to a subset of patients in each cancer entity. The presence of CD8(+) T cells within the tumor microenvironment or the invasive margin of the tumor, as well as the up-regulation of PD-L1, have emerged to be the most predictive biomarkers for clinical benefit in response to checkpoint inhibition. Although the up-regulation of immune inhibitory mechanisms is one mechanism of immune escape, commonly used by T-cell-inflamed tumors, exclusion of an anti-tumor specific T-cell infiltrate displays another even more potent mechanism of immune escape. This review will contrast the mechanisms of immunogenic, T-cell-inflamed, and the novel concept of non-immunogenic, non-T-cell-inflamed, adaptive immune escape.

Keywords
checkpoint blockade immune evasion immunotherapy oncogenes
MeSH Terms
Adaptive Immunity Animals Humans Immunotherapy/methods Inflammation/immunology Lymphocytes, Tumor-Infiltrating/immunology Neoplasms/immunology,therapy T-Lymphocytes/immunology Tumor Escape Tumor Microenvironment
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Spranger Stefani
Department of Pathology, The University of Chicago, GCIS W423H, Chicago, IL 60637, USA [email protected].
References (72)
72 references, click to expand
  1. Neutralizing tumor-promoting chronic inflammation: a magic bullet?
    Science. 2013 Jan 18;339(6117):286-91 PMID: 23329041
  2. The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells.
    Immunity. 2013 Feb 21;38(2):237-49 PMID: 23313588
  3. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  4. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
    Cancer Res. 1998 Aug 15;58(16):3491-4 PMID: 9721846
  5. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice.
    Genesis. 2006 May;44(5):262-7 PMID: 16676322
  6. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
    Nature. 2015 Jul 9;523(7559):231-5 PMID: 25970248
  7. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.
    Cancer Cell. 2011 Jun 14;19(6):715-27 PMID: 21665146
  8. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Nature. 2014 Nov 27;515(7528):568-71 PMID: 25428505
  9. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.
    Immunity. 2016 Feb 16;44(2):343-54 PMID: 26872698
  10. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.
    Br J Cancer. 2013 Oct 29;109(9):2412-23 PMID: 24129241
  11. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins.
    Int J Cancer. 2014 Feb 1;134(3):563-74 PMID: 23873187
  12. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.
    Mol Cancer Res. 2015 Mar;13(3):493-501 PMID: 25351767
  13. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Science. 2015 Apr 3;348(6230):124-8 PMID: 25765070
  14. Prevention of allogeneic fetal rejection by tryptophan catabolism.
    Science. 1998 Aug 21;281(5380):1191-3 PMID: 9712583
  15. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  16. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
    Cancer Discov. 2016 Feb;6(2):202-16 PMID: 26645196
  17. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.
    Cancer Cell. 2014 Nov 10;26(5):638-52 PMID: 25446897
  18. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer.
    Cancer Res. 2008 Nov 15;68(22):9459-68 PMID: 19010921
  19. T cell exhaustion.
    Nat Immunol. 2011 Jun;12(6):492-9 PMID: 21739672
  20. Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer.
    Nat Med. 2015 Feb;21(2):117-9 PMID: 25654601
  21. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
    N Engl J Med. 2015 May 21;372(21):2006-17 PMID: 25891304
  22. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.
    Cancer Cell. 2011 Jan 18;19(1):72-85 PMID: 21251614
  23. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Science. 2011 Mar 25;331(6024):1565-70 PMID: 21436444
  24. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
    Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61 PMID: 17875753
  25. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    Nat Genet. 2009 May;41(5):544-52 PMID: 19282848
  26. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
    Cell Rep. 2014 Oct 9;9(1):75-89 PMID: 25263564
  27. CTLA-4 control over Foxp3+ regulatory T cell function.
    Science. 2008 Oct 10;322(5899):271-5 PMID: 18845758
  28. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.
    Science. 2008 Nov 14;322(5904):1097-100 PMID: 19008445
  29. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells.
    Cancer Res. 2012 Aug 1;72(15):3735-43 PMID: 22593190
  30. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
    J Exp Med. 2010 Sep 27;207 (10 ):2187-94 PMID: 20819927
  31. Improved survival with ipilimumab in patients with metastatic melanoma.
    N Engl J Med. 2010 Aug 19;363(8):711-23 PMID: 20525992
  32. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
    Cell. 2004 Aug 6;118(3):285-96 PMID: 15294155
  33. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
    Nature. 2015 Nov 12;527(7577):249-53 PMID: 26503055
  34. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis.
    Cancer Res. 2012 Jun 15;72(12):2990-9 PMID: 22659452
  35. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
    J Clin Invest. 2011 Jun;121(6):2350-60 PMID: 21555851
  36. Innate and adaptive immune cells in the tumor microenvironment.
    Nat Immunol. 2013 Oct;14(10):1014-22 PMID: 24048123
  37. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  38. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
    Clin Cancer Res. 2013 Jan 15;19(2):393-403 PMID: 23204132
  39. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.
    Cancer Cell. 2012 Mar 20;21(3):402-17 PMID: 22439936
  40. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
    Nature. 2012 Feb 08;482(7385):400-4 PMID: 22318521
  41. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
    J Exp Med. 2000 Oct 2;192(7):1027-34 PMID: 11015443
  42. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    PLoS One. 2011 Apr 29;6(4):e19499 PMID: 21559358
  43. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
    Sci Transl Med. 2013 Aug 28;5(200):200ra116 PMID: 23986400
  44. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.
    J Clin Invest. 2014 Jun;124(6):2425-40 PMID: 24812664
  45. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
    J Clin Oncol. 2014 Apr 1;32(10):1020-30 PMID: 24590637
  46. PD-1 and its ligands in tolerance and immunity.
    Annu Rev Immunol. 2008;26:677-704 PMID: 18173375
  47. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression.
    Oncogene. 2006 Oct 30;25(51):6817-30 PMID: 17072330
  48. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
    Nature. 2007 Feb 8;445(7128):656-60 PMID: 17251933
  49. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
    Cancer Res. 2009 Apr 1;69(7):3077-85 PMID: 19293190
  50. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.
    Nat Commun. 2015 Jun 25;6:7458 PMID: 26109379
  51. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
    J Immunother Cancer. 2014 Feb 18;2:3 PMID: 24829760
  52. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
    Cancer Cell. 2011 Dec 13;20(6):741-54 PMID: 22172720
  53. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells.
    J Exp Med. 2013 Sep 23;210(10):2057-69 PMID: 24043758
  54. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer.
    J Pathol. 1997 Jul;182(3):318-24 PMID: 9349235
  55. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Nature. 2015 Apr 16;520(7547):373-7 PMID: 25754329
  56. Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer.
    Immunol Rev. 2012 Mar;246(1):327-45 PMID: 22435564
  57. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
    Immunity. 2014 Nov 20;41(5):830-42 PMID: 25517615
  58. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
    Nature. 2014 Nov 27;515(7528):577-81 PMID: 25428507
  59. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
    Cell Rep. 2015 May 19;11(7):1018-30 PMID: 25959818
  60. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
    J Exp Med. 2011 Sep 26;208(10):2005-16 PMID: 21930765
  61. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.
    Nat Med. 2004 Jan;10(1):48-54 PMID: 14702634
  62. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells.
    Nat Immunol. 2007 Dec;8(12):1353-62 PMID: 17982458
  63. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    N Engl J Med. 2015 Jul 2;373(1):23-34 PMID: 26027431
  64. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo.
    J Exp Med. 2006 Mar 20;203(3):505-11 PMID: 16533880
  65. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
    Sci Transl Med. 2012 Mar 28;4(127):127ra37 PMID: 22461641
  66. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    N Engl J Med. 2014 Dec 4;371(23 ):2189-99 PMID: 25409260
  67. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo.
    J Immunol. 2006 Oct 1;177(7):4376-83 PMID: 16982872
  68. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
    Nature. 2004 Sep 23;431(7007):461-6 PMID: 15329734
  69. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
    J Exp Med. 2007 Jun 11;204(6):1257-65 PMID: 17502665
  70. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.
    J Immunol. 2005 Apr 1;174(7):3925-31 PMID: 15778348
  71. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma.
    J Hepatol. 2015 Mar;62(3):607-16 PMID: 25450711
  72. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine.
    J Immunol. 2006 Nov 15;177(10):6780-6 PMID: 17082591
Article Info
Journal
International immunology
Abbr.
Int Immunol
ISSN
1460-2377
DOI
10.1093/intimm/dxw014
Email
[email protected]
Published
2016-00-00
Epub
2016-00-17
Pages
383-91
Language
English
Region
England
NLM ID
8916182
PMCID
PMC4986232
Subset
IM
Grants
NCI NIH HHS · K99 CA204595 · United States
NCI NIH HHS · R00 CA204595 · United States
External Links
PubMed source DOI: 10.1093/intimm/dxw014 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2